undamentalytics Newsletter
Sign in

Cue Biopharma, Inc. (CUE) stock

Add to watchlist

Add holding +

NASDAQ: CUE Nasdaq Biotechnology Next results ~November 30, 2026

C+ Fundamentals grade

Cue Biopharma, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$5.0

Forward price-to-sales vs peers

Base case. Range ~$5.0–$20. Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Cue Biopharma, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 3 selling5 purchases and 15 sales by directors and officers, last 12 monthsInsider trades

Value diary

Our note on each quarter Cue Biopharma files

Where Cue Biopharma stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $38m, up 354.4% on a year earlier, faster than the 309.6% growth a quarter earlier. That growth ranks 13 of 122 among the biotechnology companies we cover. Free-cash-flow margin rose to -133.2% from -341.7% a year earlier. Operating margin widened to -262.0% from -475.2%. The diluted share count is up 1286.3% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 2 of our 2 financial-health checks. Our price-to-sales vs peers value is $15.14 a share, against a share price of $21.95.

Source: 10-Q filed August 14, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 30, 2026 (estimated)

Cue Biopharma, Inc.'s trailing-twelve-month revenue grew 354.4% year on year, with a free-cash-flow margin of -133.2%. Where it stands out: revenue growth of 354.4% ranks 18 of 172 biotechnology companies we cover. Where it lags: change in share count of 74.2% ranks 148 of 156 biotechnology companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 77.1% while net income fell 321.9%: a 245pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 354.4% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Growth speeding up. The growth rate is 44.8 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 213.2 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Loss-making. Operating margin is -262.0%: costs exceed revenue.
  • Burning cash. Free cash flow was -133.2% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 69.1% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 74.2% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 202% and a beta of 2.8 against the S&P 500.
  • Heavily shorted. 11.5% of the shares available to trade are sold short (1.8 days of average volume to cover).

Latest results: FY2026 Q2

Filed August 14, 2026
Earnings per share
-$24.14 against an average estimate of -$1.69: missed by 1328.4%
Revenue
$8m, up 166.7% on a year earlier
Share reaction
-11.1% in the first session after the results on August 14, 2026, against -0.7% for the S&P 500

Cue Biopharma's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-6.9%
  • 1 week+5.3%
  • 1 month-24.1%
  • This year+112.2%
  • 1 year-15.7%
  • 5 years-95.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$37.7M
Operating margin
-262.0%
Net margin
-435.8%
EPS (TTM, diluted)
$-57.08

Growth

Revenue growth
+354.4%
Change in growth rate
+44.8 pts
Share count change
+74.2%

Cash

Free cash flow (TTM)
-$50.2M
FCF margin
-133.2%
Stock pay % of revenue
69.1%

Earnings

Last results
August 14, 2026
Next results (est.)
November 30, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results
  3. Insider trade
  4. Leadership
  5. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Cue Biopharma, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Cue Biopharma, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 12.7%: the 10-year Treasury yield (4.9%) plus a beta of 1.72 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.3 ~$1.0–$1.6 Left out: out of range vs price (0.07x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$5.0 ~$5.2–$20 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$5.0 ~$5.0–$20 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Cue Biopharma, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20182019202020212022202320242025
Share price$141.00$476.25$375.30$339.30$85.50$79.20$32.70$9.15
Market value$2.8bn$10.5bn$10.8bn$10.6bn$3.0bn$3.6bn$1.8bn$867m
+ Net debt (− = net cash)−$21m−$44m−$75m−$64m−$42m−$40m−$18m−$27m
Enterprise value$2.8bn$10.5bn$10.7bn$10.6bn$3.0bn$3.6bn$1.8bn$840m
Multiples
Price / sales n/mn/mn/mn/mn/mn/m198.3x31.6x
Price / earnings ————————
Price / free cash flow ————————
EV / EBITDA ————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

8 /100

Weak moat

How hard Cue Biopharma's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -70.9% of total assets over 9 years.

  • Durability 10 / 20

    Operating margin has been a median -692.5%; its worst year was -2952.7%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 7 years, at a median -465.2% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 217.6% over five years; stock-based pay has been a median 141.5% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$25.01 −198% $16m −43%
Next −$7.44 +70% $9m −45%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +276.7% on 90 days ago. In the last 30 days, 0 analysts raised Cue Biopharma, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Cue Biopharma, Inc., last 90 days
−$30.00 −$20.00 −$10.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$6.64 Current fiscal year, 60 days ago: −$6.64 Current fiscal year, 30 days ago: −$21.45 Current fiscal year, 7 days ago: −$25.01 Current fiscal year, Now: −$25.01 −$25.01 Next fiscal year, 90 days ago: −$9.45 Next fiscal year, 60 days ago: −$9.45 Next fiscal year, 30 days ago: −$6.83 Next fiscal year, 7 days ago: −$7.44 Next fiscal year, Now: −$7.44 −$7.44

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$6.64−$9.45
60 days ago −$6.64−$9.45
30 days ago −$21.45−$6.83
7 days ago −$25.01−$7.44
Now −$25.01−$7.44

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$1.69 −$24.14 −1328.4%
Dec 2025 −$2.70 $0.30 +111.1%
Sept 2025 −$2.55 −$2.10 +17.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 14, 2026

No numeric guidance in Cue Biopharma, Inc.'s latest earnings release (filed August 14, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

3 analysts, Oct 2026
Buy3100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202633
  2. Sep 202633
  3. Aug 202622

Counts of recommendations published by analysts covering Cue Biopharma, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
11.5%
of tradable shares
Days to cover
1.8
at average volume
Short interest, 1 month
+139%
to October 15, 2026
Held by institutions
23%
of shares
Held by insiders
15.1%
of shares
Employees
29
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CUE−10%−75%−7%−59%−72%+112%
Industry peers (median)−36%−56%−18%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CUE50%33%50%25%42%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CUE−39%−82%−65%−85%−86%−58%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since January 2, 2018: 99% from June 2, 2020 to April 6, 2026. Getting back needed a 17262% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$5.31 – $37.84
From 52-week high
−48.7%
vs 50-day average
−23.6%
vs 200-day average
−8.4%
Volatility (1 year)
202%
Beta vs S&P 500
2.81

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
1 up, 11 down
typical move ±8.3%
After a week
4 up, 8 down
typical move ±13.5%
After a month
4 up, 8 down
typical move ±33.1%
Results releasedNext dayS&P 500 next day5 days21 days
August 14, 2026 −11.1% −0.7% −22.8% +1.8%
March 16, 2026 −4.2% +1.3% −6.3% +154.9%
November 12, 2025 −9.2% −1.6% −15.1% −28.7%
August 12, 2025 −2.5% +1.4% −1.8% −7.8%
May 12, 2025 −1.5% +4.0% −9.4% −18.1%
April 15, 2025 −1.5% −2.5% +5.7% −8.5%
March 31, 2025 −18.5% +1.0% −32.0% −17.9%
November 14, 2024 −17.0% −1.9% −31.3% −32.0%
May 9, 2024 −8.9% +0.7% −8.9% −24.6%
May 19, 2020 +8.3% +0.7% +2.3% −4.4%
March 17, 2020 −15.5% +0.1% +20.1% +59.8%
November 12, 2019 −2.0% +0.2% +6.6% +38.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Cue Biopharma, Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Cue Biopharma, Inc.
$0 $10M $20M $30M $40M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $3.8M Revenue (TTM), FY23 Q4: $5.5M Revenue (TTM), FY24 Q1: $7M Revenue (TTM), FY24 Q2: $8.3M Revenue (TTM), FY24 Q3: $9.5M Revenue (TTM), FY24 Q4: $9.3M Revenue (TTM), FY25 Q1: $8M Revenue (TTM), FY25 Q2: $8.3M Revenue (TTM), FY25 Q3: $7.1M Revenue (TTM), FY25 Q4: $27.5M Revenue (TTM), FY26 Q1: $32.7M Revenue (TTM), FY26 Q2: $37.7M $37.7M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $3.8M
FY23 Q4 $5.5M
FY24 Q1 $7M
FY24 Q2 $8.3M
FY24 Q3 $9.5M
FY24 Q4 $9.3M
FY25 Q1 $8M
FY25 Q2 $8.3M
FY25 Q3 $7.1M
FY25 Q4 $27.5M
FY26 Q1 $32.7M
FY26 Q2 $37.7M
Revenue growth, TTM YoY Cue Biopharma, Inc.
-500% 0% 500% 1000% 1500% 2000% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -59.1% Revenue growth, TTM YoY, FY23 Q4: 341.0% Revenue growth, TTM YoY, FY24 Q1: 1525.0% Revenue growth, TTM YoY, FY24 Q2: 364.0% Revenue growth, TTM YoY, FY24 Q3: 149.5% Revenue growth, TTM YoY, FY24 Q4: 69.2% Revenue growth, TTM YoY, FY25 Q1: 13.8% Revenue growth, TTM YoY, FY25 Q2: -0.1% Revenue growth, TTM YoY, FY25 Q3: -25.5% Revenue growth, TTM YoY, FY25 Q4: 195.7% Revenue growth, TTM YoY, FY26 Q1: 309.6% Revenue growth, TTM YoY, FY26 Q2: 354.4% 354.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -59.1%
FY23 Q4 341.0%
FY24 Q1 1525.0%
FY24 Q2 364.0%
FY24 Q3 149.5%
FY24 Q4 69.2%
FY25 Q1 13.8%
FY25 Q2 -0.1%
FY25 Q3 -25.5%
FY25 Q4 195.7%
FY26 Q1 309.6%
FY26 Q2 354.4%
Operating margin (TTM) Cue Biopharma, Inc.
-1500% -1000% -500% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -1392.2% Operating margin (TTM), FY23 Q4: -949.9% Operating margin (TTM), FY24 Q1: -732.7% Operating margin (TTM), FY24 Q2: -582.2% Operating margin (TTM), FY24 Q3: -479.4% Operating margin (TTM), FY24 Q4: -446.9% Operating margin (TTM), FY25 Q1: -514.7% Operating margin (TTM), FY25 Q2: -475.2% Operating margin (TTM), FY25 Q3: -537.5% Operating margin (TTM), FY25 Q4: -96.7% Operating margin (TTM), FY26 Q1: -59.9% Operating margin (TTM), FY26 Q2: -262.0% -262.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -1392.2%
FY23 Q4 -949.9%
FY24 Q1 -732.7%
FY24 Q2 -582.2%
FY24 Q3 -479.4%
FY24 Q4 -446.9%
FY25 Q1 -514.7%
FY25 Q2 -475.2%
FY25 Q3 -537.5%
FY25 Q4 -96.7%
FY26 Q1 -59.9%
FY26 Q2 -262.0%
FCF margin (TTM) Cue Biopharma, Inc.
-1500% -1000% -500% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -1034.5% FCF margin (TTM), FY23 Q4: -727.9% FCF margin (TTM), FY24 Q1: -555.1% FCF margin (TTM), FY24 Q2: -465.2% FCF margin (TTM), FY24 Q3: -402.0% FCF margin (TTM), FY24 Q4: -391.9% FCF margin (TTM), FY25 Q1: -436.5% FCF margin (TTM), FY25 Q2: -341.7% FCF margin (TTM), FY25 Q3: -420.0% FCF margin (TTM), FY25 Q4: -79.6% FCF margin (TTM), FY26 Q1: -75.2% FCF margin (TTM), FY26 Q2: -133.2% -133.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -1034.5%
FY23 Q4 -727.9%
FY24 Q1 -555.1%
FY24 Q2 -465.2%
FY24 Q3 -402.0%
FY24 Q4 -391.9%
FY25 Q1 -436.5%
FY25 Q2 -341.7%
FY25 Q3 -420.0%
FY25 Q4 -79.6%
FY26 Q1 -75.2%
FY26 Q2 -133.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 1 3 3 15 1 5 9 27 38
EBITDA −38 −36 −44 −42 −52 −52 −41 −26 −97
Operating income −39 −37 −45 −44 −53 −52 −42 −27 −99
Net income −39 −37 −45 −44 −53 −51 −41 −27 −164
Diluted EPS −$1.94 −$1.66 −$1.56 −$1.41 −$1.49 −$1.11 −$0.72 −$0.28 —
Growth (year on year)
Revenue — +202.7% −8.8% +373.7% −91.7% +341.0% +69.2% +195.7% +354.4%
Margins
EBITDA margin <−999% <−999% <−999% −284.1% <−999% −939.8% −442.6% −93.2% −258.4%
Operating margin <−999% <−999% <−999% −292.6% <−999% −949.9% −446.9% −96.7% −262.0%
Net margin <−999% <−999% <−999% −295.6% <−999% −924.1% −438.0% −96.9% −435.8%
Free-cash-flow margin <−999% −891.9% <−999% −266.0% <−999% −727.9% −391.9% −79.6% −133.2%
Cash flow
Cash from operations −26 −31 −32 −39 −42 −40 −36 −22 −50
Capital spending 2 0 1 1 0 0 0 0 0
Free cash flow −28 −31 −33 −40 −42 −40 −36 −22 −50
Stock-based pay 7 7 10 12 9 8 7 5 26
Free cash flow after stock pay −35 −37 −44 −51 −51 −48 −43 −27 −76
Balance sheet
Cash 21 44 75 64 52 49 22 27 17
Total debt 0 0 0 0 10 8 4 — 0
Net debt (negative = net cash) −21 −44 −75 −64 −42 −40 −18 −27 −17
Diluted shares 20m 22m 29m 31m 36m 46m 56m 95m —
Returned to shareholders
Buybacks — 0 0 1 0 0 — — —
Total returned — 0 0 1 0 0 — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $31m
Short-term assets $27mLonger-term assets $4m
What it owes, and who funded it · $31m
Short-term liabilities $21mLonger-term liabilities $7mShareholders' equity $2m
  • Short-term assets cover short-term liabilities $27m of assets due within a year against $21m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $27m short-term assets against $7m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Cue Biopharma, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+74.2%
year over year
R&D spending
205.0%
of revenue
Days sales outstanding
52 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated CUE ZYME NBTX FHTX CCCC BHST Median
Revenue, last 12 months $38m $37m $37m $37m $35m $35m $56m
Revenue growth, last 12 months 354.4% −69.8% 678.4% 52.0% 2.3% 37.0% 12.6%
Revenue growth, 3-year average 176.2% −56.4% — 19.1% 29.8% — 13.7%
Revenue growth, latest quarter 166.7% −90.6% — 112.7% 2.8% — 10.2%
Operating margin −262.0% −419.0% −33.2% −198.0% −319.0% −16.2% −189.4%
Operating margin, 3-year average −439.8% −235.1% — −284.9% −361.6% — −363.5%
Net margin −435.8% −404.0% −73.5% −175.8% −289.4% −32.3% −169.8%
Cash from operations / revenue −132.9% −321.4% −102.5% −229.3% −242.2% −20.9% −168.0%
Free-cash-flow margin −133.2% −324.7% −104.2% −229.4% −243.7% −27.8% −162.4%
Free-cash-flow margin, 3-year average −313.4% −168.9% — −306.5% −255.9% — −310.0%
Stock pay / revenue 69.1% 89.6% 10.9% 27.0% 40.8% 2.4% 20.0%
Change in share count 74.2% −2.2% 1.2% 5.9% 10.4% — 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 354.4% 12.6% 18 of 172
Change in growth rate Growth +44.8pp -0.1pp 29 of 172
Operating margin Profitability -262.0% -189.4% 99 of 175
Net margin Profitability -435.8% -157.3% 123 of 180
Free-cash-flow margin Cash generation -133.2% -145.4% 87 of 176
Stock pay as % of revenue Cash generation 69.1% 19.2% 126 of 179
Change in share count Balance sheet 74.2% 7.9% 148 of 156
Days sales outstanding Balance sheet 52 days 75 days 31 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

13F filings for June 30, 2026
Reported value
$51.8M
Institutions reporting
48
Shares held vs prior quarter
▲ 96449.9%
Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Bleichroeder LP $11.7M 371K 22.6% New
Driehaus Capital Management LLC $9.2M 292K 17.8% New
Vanguard Capital Management LLC $5.1M 162K 9.9% New
Ikarian Capital, LLC $3.3M 104K 6.4% New
Tetragon Partners Gp Ltd $3M 94K 5.7% New
Stempoint Capital LP $2.1M 67K 4.1% New
Blackrock, Inc. $1.8M 58K 3.5% New
ADAR1 Capital Management, LLC $1.7M 55K 3.4% New
Lion Point Capital, LP $1.7M 53K 3.2% New
Squadron Capital Management LLC $1.6M 50K 3.0% New
Diadema Partners LP $1.5M 48K 2.9% New
Geode Capital Management, LLC $1.5M 48K 2.9% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Cue Biopharma, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $99,719 5 trades by 1 insider, last 12 months Insider sales History → $2.4M 15 trades by 3 insiders · 0% under pre-set plans
Net ▼ $2.3M net selling
Insider Date Trade Shares Price Value
Lin Shao-Lee Chief Executive Officer October 12, 2026 Sell 1,087 $28.05 $30,490
Lin Shao-Lee Chief Executive Officer October 12, 2026 Sell 10,000 $27.50 $275,000
Meluzio Michael Vincent VP, Prin. Accounting Officer October 12, 2026 Sell 1,144 $28.05 $32,089
Ray Sumita Chief Legal Compliance Officer October 12, 2026 Sell 1,844 $28.05 $51,724
Lin Shao-Lee Chief Executive Officer August 13, 2026 Sell 2,375 $28.11 $66,761
Lin Shao-Lee Chief Executive Officer August 13, 2026 Sell 10,460 $29.48 $308,361
Lin Shao-Lee Chief Executive Officer August 13, 2026 Sell 5,423 $27.19 $147,451
Meluzio Michael Vincent VP, Prin. Accounting Officer August 13, 2026 Sell 1,519 $29.37 $44,613
Meluzio Michael Vincent VP, Prin. Accounting Officer August 13, 2026 Sell 4,106 $30.35 $124,617
Meluzio Michael Vincent VP, Prin. Accounting Officer August 13, 2026 Sell 3 $31.13 $93
Ray Sumita Chief Legal Compliance Officer August 13, 2026 Sell 4 $31.13 $125
Ray Sumita Chief Legal Compliance Officer August 13, 2026 Sell 6,442 $30.35 $195,515

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 30, 2026 estimated from the company's past filing pattern, not announced

  • August 14, 2026
  • March 16, 2026
  • November 12, 2025
  • August 12, 2025
  • May 12, 2025
  • April 15, 2025

Recent SEC filings

Data status

When each part of this page on Cue Biopharma, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Cue Biopharma, Inc. in brief

What does Cue Biopharma, Inc. do?
Cue Biopharma, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Cue Biopharma, Inc.'s stock ticker?
Cue Biopharma, Inc. trades under the ticker CUE on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Cue Biopharma, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Cue Biopharma, Inc. reported revenue of $37.7M, 354.4% higher than a year earlier, according to its SEC filings.
What is Cue Biopharma, Inc.'s free cash flow?
Cue Biopharma, Inc.'s free-cash-flow margin is -133.2% of revenue over the trailing twelve months, ranking 87 of the 176 biotechnology companies we cover.
Who are Cue Biopharma, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Bleichroeder LP, Driehaus Capital Management LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Cue Biopharma, Inc.'s market cap?
On December 31, 2025, Cue Biopharma, Inc.'s market capitalisation was about $867M and net debt of -$27.1M. Market figures come from third-party market data and may be delayed.
Who are Cue Biopharma, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Cue Biopharma, Inc. are Zymeworks Inc., Nanobiotix S.a., Foghorn Therapeutics Inc., C4 Therapeutics, Inc. and Bioharvest Sciences Inc. The side-by-side comparison below sets their revenue, margins and growth against Cue Biopharma, Inc.'s.
Are insiders buying or selling Cue Biopharma, Inc. stock?
Over the last 12 months, Cue Biopharma, Inc.'s directors and officers reported 5 open-market purchases and 15 sales on Form 4. The insider trading page charts every trade.
When is Cue Biopharma, Inc.'s next earnings date?
Around November 30, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Cue Biopharma, Inc. announces its own schedule.